Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer
Medical Hypotheses, 06/25/09
Kim K et al. - Randomized clinical trials comparing neoadjuvant chemotherapy (NAC) followed by surgery with initial surgery in cervical cancer reported conflicting results. The authors provided a hypothesis explaining the different outcomes between trials. The empirical data showed that patients who underwent NAC followed by surgery and were classified as low-risk based on pathologic parameters had unexpectedly high recurrence rate.
Related Articles
Macrophage migration inhibitory factor expression in cervical cancer
Journal of Cancer Research & Clinical Oncology, 11/23/09
Relevance Score: 71%
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study : The Lancet Oncology
The Lancet Oncology - Online First, 10/12/09
Relevance Score: 70%
Effectiveness of cervical cancer screening at different ages
Women's Health, 10/30/09
Relevance Score: 69%
A survey of the knowledge and attitude of Jordanian obstetricians and gynaecologists to cervical cancer screening
Journal of Obstetrics and Gynaecology, 10/29/09
Relevance Score: 69%
Interleukin-12 gene polymorphism and cervical cancer risk
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 69%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


